-
Mashup Score: 27Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial [NCT00541047] - 22 day(s) ago
Long-term results from RADICALS-RT confirm adjuvant RT after radical prostatectomy increases the risk of urinary and bowel morbidity, but does not meaningfully improve disease control. An observation policy with salvage RT for PSA failure should be the current standard after radical prostatectomy.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Oncogenic extrachromosomal DNA identification using whole-genome sequencing from formalin-fixed glioblastomas - 1 month(s) ago
Glioblastoma, an area of urgent unmet clinical need, is the most common intrinsic brain cancer and frequently contains extrachromosomal DNA (ecDNA). EcDNA is increasingly recognized as a driver of cancer evolution and a mediator of therapy resistance1,2. Recent studies have implicated ecDNA as a prognostic marker across many cancer types, and a driver of glioblastoma, with emerging clinical trials aiming to leverage knowledge of ecDNA status or therapeutically target ecDNA directly3.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 36Response-guided neoadjuvant sacituzumab govitecan for localized triple negative breast cancer: results from the NeoSTAR trial - 1 month(s) ago
Sacituzumab govitecan (SG), a novel antibody-drug conjugate targeting Trop2, is approved for pre-treated metastatic triple negative breast cancer (mTNBC). We conducted an investigator-initiated clinical trial evaluating neoadjuvant (NA) SG (NCT04230109), and report primary results
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 14Response-guided neoadjuvant sacituzumab govitecan for localized TNBC - 1 month(s) ago
Sacituzumab govitecan (SG), a novel antibody–drug conjugate (ADC) targeting TROP2, is approved for pre-treated metastatic triple-negative breast cancer (mTNBC). In this podcast, Annals of Oncology Edi
Source: soundcloud.comCategories: General Medicine News, Onc News and JournalsTweet-
🆕The latest Annals of Oncology article of the month podcast 🎙️ is out. EiC @tompowles1 discusses with @dradityabardia the NeoSTAR trial investigating Sacituzumab Govitecan in the pre-operative setting of TNBC Soundcloud: https://t.co/H96dU2RC4l Spotify: https://t.co/eYntXN63Tv https://t.co/3o8yWAM5Ox
-
-
Mashup Score: 11New ADCs bring new questions in EGFR NSCLC and beyond - 1 month(s) ago
Antibody drug conjugates (ADCs) represent one of the fastest growing therapeutic drug classes in solid tumor oncology. The ability to combine highly potent payload moieties with monoclonal antibodies selective for tumor specific antigens has shifted our approach in treating patients with multiple different tumor types, including non-small cell lung cancer (NSCLC). Currently three ADCs in NSCLC have received accelerated approval or breakthrough therapy designation from the FDA, including trastuzumab deruxtecan (T-DXd) for HER2-mutated NSCLC, telisotuzumab vedotin (Teliso-V) for NSCLC with MET overexpression, and patritumab deruxtecan (HER3-DXd) for EGFR-mutated NSCLC.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Genome-wide association study and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer - 2 month(s) ago
The incidence of early-onset colorectal cancer (EOCRC; diagnosed <50 years of age) is rising globally; however, the causes underlying this trend are largely unknown. Colorectal cancer (CRC) has strong genetic and environmental determinants, yet common genetic variants and causal modifiable risk factors underlying EOCRC are unknown. We conducted the first EOCRC-specific genome-wide association study (GWAS) and Mendelian randomization analyses to explore germline genetic and causal modifiable risk factors associated with EOCRC.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 36European cancer mortality predictions for the year 2024 with focus on colorectal cancer - 2 month(s) ago
We predicted cancer mortality figures for 2024 for the European Union (EU), its five most populous countries, and the UK. We focused on mortality from colorectal cancer (CRC).
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11
Chylous effusion is a rare side effect observed during treatment with multikinase inhibitors (MKI) or selective RET tyrosine kinase inhibitors (TKIs) [1]. Pleura (12/22; 54%), peritoneum (5/22; 23%), or both (5/22; 23%) were common sites for chylous effusion. Selpercatinib (15/217; 7%) and MKIs (7/7371; <1%) were the most frequent causes. No confirmed effusion cases were observed with pralsetinib, but two RET rearranged NSCLC patients on pralsetinib had chylous ascites in a recent case series [2].
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET - 2 month(s) ago
18F-FES PET/CT is considered an accurate diagnostic tool to determine whole-body endocrine responsiveness. In the ET-FES trial, we evaluated 18F-FES PET/CT as a predictive tool in ER+/HER2- metastatic breast cancer (MBC).
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 20Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer - 2 month(s) ago
Immunotherapy has transformed the endometrial cancer treatment landscape , particularly for those exhibiting mismatch repair deficiency (MMRd/MSI-H). A growing body of evidence supports the integration of immunotherapy with chemotherapy as a first-line treatment strategy. Recently, findings from ongoing trials such as RUBY (NCT03981796), NRG-GY018 (NCT03914612), AtTEnd (NCT03603184), and DUO-E (NCT04269200) have been disclosed.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
❓What timing for radiotherapy☢️after radical prostatectomy for prostate cancer? Results of the RADICALS-RT randomized trial of adjuvant RT vs observation with salvage RT for PSA failure are published in Annals of Oncology @mattsydes @mrcctu @pcaparker https://t.co/DJpwC4edhl